A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Parabilis Medicines, Inc.
Qilu Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Incyte Corporation
National Cancer Institute (NCI)
Sanofi